Fenben lab fenbendazol is a broad-spectrum anthelmintic drug that binds to the b-tubulins of parasitic nematodes and inhibits their ability to dimerize into microtubules, which form a part of the cell’s cytoskeleton. Microtubules are required for protein synthesis and other metabolic processes, including cell division. Inhibition of tubulin polymerization has been reported to cause the death of nematode cells. In addition to demonstrating antiparasitic activity, fenbendazole has been shown to exert antineoplastic properties by binding and blocking the growth of tumors in animals.
The present study was undertaken to evaluate the effect of a low dose (150 ppm) of fenbendazole in combination with supplemented vitamins on the growth of human lymphoma cancer cells in SCID mice. The fenbendazole used in this study was dissolved in sterile, pyrogen-free physiologic saline and administered i.p. To minimize radiation exposure of critical normal tissues, tumors were irradiated using a Siemens Stabilipan (Malvern PA, USA) with a 250 kV beam and 2 mm Al filtration.
Mice treated with fenbendazole in conjunction with the irradiated tumors developed significantly smaller lung metastases than mice that received fenbendazole alone. These results were not attributed to a direct antitumor effect of the fenbendazole, because the fenbendazole-treated mice also had lower initial blood counts than the control mice, and this could have influenced the initial tumor volume.
Fenbendazole is a potent inhibitor of many species of parasitic nematodes, including pinworms, giardiasis, roundworms, hookworms, and Taenia solium. It also has antineoplastic properties against gastrointestinal parasites and prevents transplacental transmission of T. canis in dogs. In addition, fenbendazole has a variety of extra-label uses for domestic and wild cats, including the prevention of pulmonary paragogimiasis. fenbendazole for cancer